Atlas of Intracranial Recordings on Cortical Responses After Functional tACS (AIRCRAFT)

Capital Medical University

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Transcranial Alternating Current Stimulation

Treatments: Device: tACS

Study type: Interventional

Funder types: Other

Identifiers

NCT04560959

LYS-[2020]-051

Details and patient eligibility

About

By analyzing the SEEG recordings, we explore the range of cortical functional responses to strings of 77.5Hz stimulations delivered by tACS,

Enrollment: 30 estimated patients

Sex: All

Ages: 14 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All epileptic patients that would receive the implantation of SEEG electrodes, regardless of the seizure locations;
• There was no metal implantation before;
• Eligible for MRI examination;
• No other lesional neurological disorders;
• Could be well informed by the study protocols.

Exclusion criteria

• Suffered from any other mental illnesses prior to the enrollment;
• Those suffering from the serious or unstable organic diseases;
• Pregnant or lactation women, and those who have a plan of pregnant;
• Patients with central nervous system tumors, acute brain injury or infection;
• Skin injured, or allergic to the exposure of the conductive gel;
• Those with implanted devices;
• Those who received modified electrical convulsive therapy, or TMS within the recent one month;
• The score of item 3 (suicidal item) in HAMD-17 equal or greater than 3;
• Enrolled in any other on going trials;
• Other situations evaluated by the researchers as inappropriate to the enrollment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

tACS arm

Experimental group

Description:

The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.

Treatment:

Device: tACS